Hypothalamic Hormones and Receptor Pharmacology

Correct Answer

C) Pan-somatostatin receptor agonist with activity at subtypes 1, 2, 3, and 5

Rationale

Pasireotide is a pan-somatostatin receptor agonist with high affinity for somatostatin receptor subtypes 1, 2, 3, and 5, with somatostatin receptor subtype 5 affinity approximately 40-fold higher than octreotide. This distinguishes it from octreotide and lanreotide, which are selective for somatostatin receptor subtypes 2 and 5. The broader receptor profile of pasireotide provides additive suppression of growth hormone and adrenocorticotropic hormone but also substantially increases hyperglycemia risk through somatostatin receptor subtype 5-mediated inhibition of insulin and incretin secretion.

Correct Answer

A) Pegvisomant

Rationale

Pegvisomant is a genetically engineered growth hormone receptor antagonist derived from native growth hormone but modified with amino acid substitutions that prevent receptor dimerization and downstream signaling. It is conjugated with polyethylene glycol chains to extend its elimination half-life. Octreotide is a somatostatin receptor subtype 2 and 5-selective analog. Tesamorelin is a growth hormone-releasing hormone analog. Macimorelin is an oral ghrelin receptor agonist used for diagnostic purposes.

Correct Answer

D) Ghrelin receptor (growth hormone secretagogue receptor type 1a) agonist

Rationale

Macimorelin is an orally bioavailable small molecule agonist at the ghrelin receptor, also called growth hormone secretagogue receptor type 1a. Ghrelin receptor activation stimulates pituitary somatotroph cells to secrete growth hormone, making macimorelin useful as a provocative agent for diagnosing adult growth hormone deficiency. It does not act at somatostatin receptors, the growth hormone-releasing hormone receptor, or the growth hormone receptor itself.

Correct Answer

B) Growth hormone-releasing hormone analog

Rationale

Tesamorelin is a synthetic analog of native growth hormone-releasing hormone in which the full 44-amino-acid sequence is stabilized by conjugation with a trans-3-hexenoic acid group at the N-terminus, protecting the molecule from dipeptidyl peptidase-4 cleavage. It acts at the growth hormone-releasing hormone receptor on pituitary somatotrophs to stimulate endogenous growth hormone secretion. Ghrelin receptor agonism describes macimorelin. Somatostatin receptor subtype 2 and 5 agonism describes octreotide and lanreotide. Recombinant human growth hormone describes somatropin.

Correct Answer

A) Recombinant human growth hormone administered by subcutaneous injection

Rationale

Somatropin is recombinant human growth hormone, a 191-amino acid polypeptide produced by recombinant deoxyribonucleic acid technology and administered by subcutaneous injection. It cannot be given orally because the peptide bond structure is hydrolyzed in the gastrointestinal tract before absorption. Subcutaneous bioavailability is approximately 70 to 90%. Growth hormone-releasing hormone analog describes tesamorelin. Oral ghrelin receptor agonist describes macimorelin. Growth hormone receptor antagonist describes pegvisomant.

Correct Answer

C) Somatostatin receptor subtype 2 and 5-selective analog delivered as a deep subcutaneous high-viscosity autogel

Rationale

Lanreotide (Somatuline Depot) is a somatostatin receptor subtype 2 and 5-selective analog formulated as a high-viscosity aqueous gel delivered by deep subcutaneous injection from a pre-filled syringe. The gel forms a subcutaneous depot that releases lanreotide over approximately 28 days without requiring a bridging period. The intramuscular poly(lactic-co-glycolic acid) microsphere description applies to octreotide long-acting release. Pasireotide, not lanreotide, is a pan-somatostatin receptor agonist. Lanreotide has no activity at ghrelin receptors.

Correct Answer

B) Pasireotide activates somatostatin receptor subtype 5 on pancreatic beta cells and intestinal L-cells, suppressing both insulin secretion and incretin (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) release, eliminating the primary signals for postprandial insulin secretion

Rationale

Pasireotide has substantially higher affinity for somatostatin receptor subtype 5 than octreotide or lanreotide — approximately 40-fold higher. Somatostatin receptor subtype 5 is expressed on pancreatic beta cells, where its activation suppresses insulin secretion, and on intestinal L-cells and K-cells, where it suppresses secretion of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Incretins normally amplify glucose-stimulated insulin secretion; their suppression compounds the direct effect on beta cells. Octreotide and lanreotide have lower somatostatin receptor subtype 5 affinity, producing less insulin and incretin suppression. Pasireotide does not act at growth hormone receptors or hypothalamic insulin-sensitizing pathways.

Correct Answer

D) Dipeptidyl peptidase-4 inhibitors work by slowing the degradation of endogenous incretin hormones to amplify their action; pasireotide suppresses incretin secretion at its source, leaving little incretin activity to preserve

Rationale

Dipeptidyl peptidase-4 inhibitors prolong the action of endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide by inhibiting their enzymatic degradation. This mechanism depends on intact incretin secretion from intestinal L-cells and K-cells. Pasireotide activates somatostatin receptor subtype 5 on these cells, profoundly suppressing incretin release. With little incretin available to begin with, dipeptidyl peptidase-4 inhibition has minimal substrate to act on and provides negligible benefit. Glucagon-like peptide-1 receptor agonists and insulin are preferred because they bypass the need for endogenous incretin secretion. There is no pharmacokinetic interaction between pasireotide and dipeptidyl peptidase-4 inhibitors, and the mechanism of urinary glucose excretion is used by sodium-glucose cotransporter-2 inhibitors, not dipeptidyl peptidase-4 inhibitors.

Correct Answer

A) Pegvisomant blocks growth hormone receptors at peripheral tissues, reducing insulin-like growth factor-1 production and removing the negative feedback that insulin-like growth factor-1 normally exerts on the pituitary, allowing growth hormone secretion to increase

Rationale

Pegvisomant acts at peripheral growth hormone receptors, preventing receptor dimerization and signal transduction. As a result, hepatic insulin-like growth factor-1 production falls toward normal. Insulin-like growth factor-1 normally provides long-loop negative feedback to both the hypothalamus — stimulating somatostatin release and suppressing growth hormone-releasing hormone — and directly to pituitary somatotrophs. When insulin-like growth factor-1 falls during pegvisomant therapy, this negative feedback is reduced, and the tumor somatotrophs secrete more growth hormone. Rising serum growth hormone during pegvisomant therapy therefore indicates the drug is working, not failing; insulin-like growth factor-1 is the sole reliable monitoring marker. Pegvisomant does not stimulate somatotrophs directly, does not affect hypothalamic somatostatin, and does not induce hepatic growth hormone receptor expression.

Correct Answer

C) Somatropin induces hepatic cytochrome P450 3A4 expression, accelerating cortisol and exogenous glucocorticoid metabolism; in a patient on a fixed hydrocortisone replacement dose, the increased clearance reduces circulating glucocorticoid levels below the threshold needed to prevent adrenal crisis

Rationale

Growth hormone replacement significantly induces hepatic cytochrome P450 3A4 and cytochrome P450 2C19 activity, accelerating the metabolism of glucocorticoids including cortisol and exogenous hydrocortisone. In panhypopituitary patients who cannot increase adrenal cortisol production in response to increased clearance, a fixed hydrocortisone replacement dose may become insufficient. The result is unmasking of central adrenal insufficiency, presenting with fatigue, nausea, weight loss, and hypotension. Before starting somatropin in panhypopituitary patients, glucocorticoid adequacy must be confirmed and hydrocortisone doses may need upward adjustment. Somatropin does not suppress adrenocorticotropic hormone directly, does not activate mineralocorticoid receptors to displace cortisol, and sodium retention does not dilute glucocorticoid activity.

Correct Answer

B) Rifampin is a potent cytochrome P450 3A4 inducer; increased cytochrome P450 3A4 activity accelerates macimorelin metabolism, reducing plasma macimorelin concentrations and blunting the growth hormone stimulus, producing a falsely low peak and a false-positive diagnosis of growth hormone deficiency

Rationale

Macimorelin is metabolized primarily by cytochrome P450 3A4. Rifampin is one of the most potent inducers of cytochrome P450 3A4 available. Co-administration substantially accelerates macimorelin clearance, reducing plasma concentrations during the critical stimulation window and blunting the growth hormone secretory response. The result is a falsely low peak growth hormone, producing a false-positive diagnosis of adult growth hormone deficiency in a patient who may have normal growth hormone reserve. The package labeling specifies that strong cytochrome P450 3A4 inducers including rifampin, carbamazepine, and phenytoin should be discontinued before macimorelin testing. Rifampin does not bind the ghrelin receptor, does not stimulate somatostatin release, and macimorelin does not require central nervous system penetration for its stimulatory effect on pituitary somatotrophs.

Correct Answer

D) Somatostatin analogs inhibit cholecystokinin release from intestinal I-cells; reduced cholecystokinin impairs gallbladder contraction, causing bile stasis and promoting cholesterol crystallization and gallstone formation

Rationale

Cholecystokinin is the primary physiological stimulus for gallbladder contraction after meals. It is released from intestinal I-cells in response to dietary fat and protein. Somatostatin analogs suppress cholecystokinin secretion through somatostatin receptor activation on intestinal cells, reducing the postprandial cholecystokinin surge and impairing gallbladder contractility. Bile stasis in a poorly contracting gallbladder allows cholesterol crystallization and promotes stone formation. This is a class effect of all somatostatin analogs — octreotide, lanreotide, and pasireotide. Somatostatin analogs do not directly stimulate gallbladder mucin secretion, do not inhibit hepatic bile acid synthesis through a receptor-mediated pathway, and reduced gastrointestinal motility alone does not increase cholesterol absorption.

Correct Answer

A) Pegvisomant binds growth hormone receptors at peripheral tissues with high affinity but contains amino acid substitutions that prevent receptor dimerization; without productive dimerization, Janus kinase 2 and signal transducer and activator of transcription 5 signaling cannot be initiated, blocking insulin-like growth factor-1 synthesis

Rationale

Native growth hormone activates its receptor by binding a single growth hormone receptor molecule and inducing dimerization of two receptor subunits. This dimerization event is required to activate Janus kinase 2, which then phosphorylates and activates signal transducer and activator of transcription 5, driving insulin-like growth factor-1 gene transcription. Pegvisomant is engineered from native growth hormone with amino acid substitutions at the site-2 dimerization interface, preserving high-affinity site-1 binding to the first receptor subunit while preventing recruitment and dimerization of the second receptor subunit. Janus kinase 2 and signal transducer and activator of transcription 5 signaling cannot proceed without dimerization, and insulin-like growth factor-1 production is blocked. This peripheral receptor antagonism does not affect pituitary growth hormone secretion; serum growth hormone rises as negative feedback is lost. Pegvisomant does not internalize receptors, does not act at insulin-like growth factor-1 receptors, and has no somatostatin receptor activity.

Correct Answer

C) Growth hormone stimulates hepatic and peripheral synthesis of insulin-like growth factor-1, which has a plasma half-life of approximately 12 to 15 hours; the sustained presence of insulin-like growth factor-1 mediates the growth-promoting and anabolic effects of growth hormone throughout the dosing interval

Rationale

The short plasma half-life of somatropin (2 to 4 hours) would predict that biological effects last only a few hours after injection. However, growth hormone acts primarily by inducing insulin-like growth factor-1 synthesis in the liver and peripheral tissues. Insulin-like growth factor-1 circulates bound to insulin-like growth factor binding protein-3, which extends its half-life to approximately 12 to 15 hours. Insulin-like growth factor-1 mediates most of the growth-promoting, anabolic, and metabolic effects attributed to growth hormone. The prolonged presence of insulin-like growth factor-1 in circulation provides the pharmacodynamic basis for once-daily growth hormone administration. Tissue redistribution does not explain the pharmacodynamic duration, growth hormone-binding protein serves a regulatory rather than depot function, and subcutaneous somatropin formulations do not form sustained-release depots at the injection site.

Correct Answer

B) Pasireotide activates somatostatin receptor subtype 5 on pancreatic beta cells and intestinal incretin-secreting cells, simultaneously suppressing insulin secretion and eliminating the incretin amplification of postprandial insulin release

Rationale

The transition from somatostatin receptor subtype 2 and 5-selective octreotide to pan-receptor pasireotide substantially increases somatostatin receptor subtype 5 occupancy. Somatostatin receptor subtype 5 activation on pancreatic beta cells directly suppresses insulin secretion through Gi-mediated inhibition of adenylyl cyclase and calcium channel blockade. Somatostatin receptor subtype 5 is also expressed on intestinal L-cells secreting glucagon-like peptide-1 and K-cells secreting glucose-dependent insulinotropic polypeptide; pasireotide suppresses both incretin hormones at their source. Incretins normally amplify postprandial insulin secretion by 50 to 70%; their elimination compounds the direct beta-cell suppression. Pasireotide does not activate glucagon-secreting alpha cells to increase glucose production, does not act on hypothalamic autonomic pathways as a primary mechanism, and does not structurally mimic insulin receptor antagonists.

Correct Answer

D) Pegvisomant blocks growth hormone receptors in the liver and peripheral tissues, reducing insulin-like growth factor-1 production and thereby removing the insulin-like growth factor-1-mediated negative feedback on the pituitary; the resulting disinhibition of pituitary somatotrophs increases growth hormone secretion, making serum growth hormone an unreliable marker of treatment response when pegvisomant is used

Rationale

Pegvisomant acts peripherally to block growth hormone receptor signaling, reducing hepatic insulin-like growth factor-1 synthesis. As insulin-like growth factor-1 falls toward normal, the long-loop negative feedback it normally exerts on the hypothalamus and pituitary is reduced. The pituitary somatotroph tumor — no longer suppressed by normal insulin-like growth factor-1 — increases growth hormone output. This is an expected and mechanistically predictable pharmacodynamic consequence of effective pegvisomant therapy, not a sign of treatment failure. Normalized insulin-like growth factor-1 is the only reliable marker of biochemical response when pegvisomant is part of the regimen. Random growth hormone levels should not be used to guide pegvisomant dosing. The other options mischaracterize the pharmacodynamics: lanreotide dose adjustment is not indicated when insulin-like growth factor-1 is normal, growth hormone variability is clinically relevant in the context of rising trends, and pegvisomant does not compete with growth hormone for binding protein in a way that artefactually elevates measured growth hormone.

Correct Answer

A) Tesamorelin stimulates pulsatile endogenous growth hormone secretion by activating the growth hormone-releasing hormone receptor on pituitary somatotrophs, restoring physiological growth hormone pulsatility suppressed by increased somatostatin tone in this condition; it requires an intact pituitary and preserves negative feedback regulation

Rationale

Antiretroviral therapy-associated lipodystrophy involves excessive visceral fat accumulation driven in part by suppression of endogenous growth hormone pulsatility from increased hypothalamic somatostatin tone. Tesamorelin is a growth hormone-releasing hormone analog that acts at the growth hormone-releasing hormone receptor on pituitary somatotrophs to stimulate release of endogenous growth hormone in a physiological pulsatile pattern. This approach preserves insulin-like growth factor-1 negative feedback regulation, producing more moderate and controlled insulin-like growth factor-1 elevation than direct growth hormone replacement. It requires a functionally intact pituitary somatotroph pool. Tesamorelin does not act directly on growth hormone receptors in adipose tissue — it acts upstream at the pituitary. Tesamorelin is administered by subcutaneous injection, not orally. It has no selective adipose versus muscle receptor profile.

Correct Answer

C) Somatropin induces hepatic cytochrome P450 3A4 expression, accelerating the metabolism of exogenous hydrocortisone; the resulting reduction in circulating glucocorticoid levels unmasks the underlying central adrenal insufficiency that her fixed hydrocortisone dose had previously been compensating

Rationale

Growth hormone replacement induces hepatic cytochrome P450 3A4 and cytochrome P450 2C19 activity, accelerating the metabolism of glucocorticoids. In a panhypopituitary patient who cannot produce additional cortisol in response to increased clearance, the previously adequate hydrocortisone replacement dose becomes insufficient. The resulting relative glucocorticoid deficiency manifests as fatigue, nausea, and hypotension — the presentation of adrenal insufficiency. This interaction is particularly important in panhypopituitary patients, who have both growth hormone deficiency and central adrenal insufficiency. Glucocorticoid replacement doses should be assessed and increased if necessary before or shortly after starting somatropin. Somatropin does not stimulate adrenocorticotropic hormone from the pituitary, does not dilute cortisol through sodium retention, and does not compete with cortisol at glucocorticoid receptors.